bioAffinity Strengthens Advisory Board with Top Lung Cancer Experts
Event summary
- bioAffinity Technologies added three lung cancer specialists to its Medical and Scientific Advisory Board: David Ost (MD Anderson), Daniel Sterman (NYU Langone), and J. Scott Ferguson (UW School of Medicine).
- The appointments align with bioAffinity's focus on integrating its CyPath® Lung diagnostic test into standard care for indeterminate pulmonary nodules.
- CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules.
- The expanded advisory board includes leaders from major cancer centers and pulmonary medicine programs.
The big picture
The appointments reflect bioAffinity's strategic push to solidify CyPath® Lung as a standard diagnostic tool for early lung cancer detection. Lung cancer remains the leading cause of cancer-related deaths, and the company's focus on high-risk patient populations aligns with industry trends toward precision diagnostics. The expanded advisory board strengthens bioAffinity's clinical and scientific credibility as it competes in the rapidly evolving cancer diagnostics space.
What we're watching
- Clinical Adoption
- How the new advisory board members will accelerate CyPath® Lung's integration into clinical practice.
- Regulatory Pathway
- Whether the expanded advisory board will help navigate regulatory hurdles for broader diagnostic use.
- Competitive Positioning
- The pace at which bioAffinity can differentiate CyPath® Lung in the growing early lung cancer detection market.
Related topics